Skip to main content

Table 3 Risk of colon cancer associated with different categories of HRT formulation or administration.

From: Colon cancer risk and different HRT formulations: a case-control study

  e-case/e-ctrl Adj. OR (95% CI)
Route of administration   
   ORAL   
Ever 99/381 0.76 (0.54–1.08)
1–4 years 17/108 0.54 (0.30–1.00)
5–9 years 27/125 0.61 (0.36–1.04)
10+ years 38/103 1.14 (0.68–1.92)
   TRANSDERMAL   
Ever 24/99 1.17 (0.63–2.16)
1–4 years 6/29 0.98 (0.34–2.86)
5–9 years 5/32 0.87 (0.30–2.51)
10+ years 10/27 2.16 (0.73–6.36)
   OTHER   
Ever 11/48 0.96 (0.40–2.31)
1–4 years 1/11 n.d.
5–9 years 2/11 n.d.
10+ years 5/19 1.15 (0.30–4.35)
Form of combination   
   SEQUENTIAL FORMULATIONS   
Ever 46/191 0.80 (0.51–1.20)
1–4 years 5/49 0.47 (0.17–1.31)
5–9 years 14/66 0.66 (0.32–1.35)
10+ years 22/50 1.45 (0.70–3.04)
   CONTINUOUS-COMBINED   
Ever 40/176 0.80 (0.50–1.29)
1–4 years 8/53 0.66 (0.26–1.66)
5–9 years 12/52 0.56 (0.25–1.20)
10+ years 9/47 0.65 (0.26–1.67)
   ANY COMBINATION   
Ever 78/324 0.85 (0.59–1.21)
1–4 years 13/94 0.56 (0.28–1.12)
5–9 years 23/104 0.71 (0.40–1.24)
10+ years 28/83 1.21 (0.67–2.21)
CEE/MPA combinations   
   CEE + MPA   
Ever 3/27 n.d
1–4 years 0/9 n.d.
5–9 years 1/7 n.d.
10+ years 1/10 n.d.
   CEE or MPA   
Ever 42/142 0.64 (0.38–1.10)
1–4 years 6/36 0.44 (0.16–1.20)
5–9 years 13/46 0.63 (0.26–1.52)
10+ years 20/45 1.10 (0.49–2.47)
   No CEE, no MPA   
Ever 80/306 0.95 (0.66–1.37)
1–4 years 19/89 0.87 (0.48–1.59)
5–9 years 21/104 0.78 (0.44–1.38)
10+ years 21/73 1.11 (0.58–2.13)
Formulation content   
ONLY – HRTS   
   ESTROGEN ONLY   
Ever 55/189 0.81 (0.51–1.28)
1–4 years 8/46 0.50 (0.20–1.24)
5–9 years 14/66 0.98 (0.47–2.06)
10+ years 25/60 1.07 (0.52–2.19)
   PROGESTAGEN ONLY   
Ever 9/35 0.48 (0.17–1.37)
1–4 years 1/10 n.d.
5–9 years 2/9 n.d.
10+ years 6/12 0.57 (0.13–2.48)
Estrogen type   
   ESTRADIOL (E2)   
Ever 80/350 0.86 (0.60–1.22)
1–4 years 16/99 0.73 (0.39–1.36)
5–9 years 22/112 0.89 (0.52–1.54)
10+ years 28/92 1.10 (0.62–1.91)
   CONJUGATED EQUINE ESTROGENS (CEE)   
Ever 40/141 0.70 (0.41–1.19)
1–4 years 5/35 0.44 (0.16–1.25)
5–9 years 12/47 0.61 (0.25–1.49)
10+ years 19/49 1.30 (0.57–2.73)
Progestin type   
   NORETISTERONE ACETATE (NETA)   
Ever 42/193 0.78 (0.48–1.25)
1–4 years 7/57 0.54 (0.20–1.44)
5–9 years 13/61 0.73 (0.35–1.53)
10+ years 14/49 0.90 (0.42–1.94)
   LNG   
Ever 22/83 0.88 (0.46–1.68)
1–4 years 2/21 0.45 (0.10–2.08)
5–9 years 6/35 0.53 (0.19–1.49)
10+ years 9/19 1.64 (0.51–5.30)
   MEDROXYPROGESTERONE ACETATE (MPA)   
Ever 8/55 0.42 (0.16–1.10)
1–4 years 1/19 n.d.
5–9 years 3/13 n.d.
10+ years 3/16 n.d.
   MEDROGESTONE   
Ever 18/65 0.87 (0.43–1.73)
1–4 years 3/17 n.d.
5–9 years 4/23 n.d.
10+ years 10/19 1.81 (0.62–5.28)
   TIBOLONE   
Ever 5/14 0.91 (0.26–3.23)
1–4 years 2/6 n.d.
5–9 years 0/3 n.d.
10+ years 3/4 n.d.
  1. The categories are not mutually exclusive – (see text). Ever use and three categories of duration of use in years are presented.
  2. Conditional logistic regression: Odds ratios (OR) and 95% confidence intervals (95% CI); adjusted for age and region. No OR was calculated if the frequency of exposed cases or controls was fewer than 5 women. The only index date shown in this table is 0.5 years.
  3. e-case/e-ctrl = number of exposed cases and controls, respectively